Successful Treatment of Advanced Intrahepatic Cholangiocarcinoma With a High Tumor Mutational Burden and PD-L1 Expression by PD-1 Blockade Combined With Tyrosine Kinase Inhibitors: A Case Report

Ze Zhang1,2,3,4, Wenwen Zhang2,3,4, Hongguang Wang5, Bingyang Hu2,3,4, Zhanbo Wang6 and Shichun Lu2,3,4*

1 Medical School of Chinese People’s Liberation Army (PLA), Beijing, China, 2 Faculty of Hepato-Pancreato-Biliary Surgery, Chinese PLA General Hospital, Beijing, China, 3 Institute of Hepatobiliary Surgery of Chinese PLA, Beijing, China, 4 Key Laboratory of Digital Hepatobiliary Surgery, PLA, Beijing, China, 5 Department of Hepatobiliary Surgery, Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China, 6 Department of Pathology, Chinese PLA General Hospital, Beijing, China

Advanced intrahepatic cholangiocarcinoma (iCCA) is not suitable for surgical treatment. Guided by the concept of precision medicine, preoperative systematic treatment may reshape the clinical outcomes of advanced intrahepatic cholangiocarcinoma patients. We describe the case of a 38-year-old female who has been diagnosed with stage IV intrahepatic cholangiocarcinoma with a high tumor mutational burden and positively programmed death-ligand 1 (PD-L1) expression. The patient was treated with programmed cell death 1 (PD-1) inhibitors combined with tyrosine kinase inhibitors (TKIs). After 7 cycles of combination therapy, she underwent radical resection and no tumor cells were found in the postoperative histopathological examination. In addition, the patient’s survival time had reached 25 months, as of August 2021. To date, this is the first case of successful radical resection after combined immunotherapy with TKIs for advanced PD-L1-positive intrahepatic cholangiocarcinoma with a high tumor mutational burden (TMB). The case provides a new approach to the treatment of advanced intrahepatic cholangiocarcinoma.

Keywords: intrahepatic cholangiocarcinoma, immunotherapy, conversion therapy, PD-L1, TMB
INTRODUCTION

Intrahepatic cholangiocarcinoma is the second most common primary liver cancer after hepatocellular carcinoma, and the incidence rate of iCCA has been on the rise over recent decades (1). In the early stages of iCCA, curative resection is the preferred treatment option, but a majority of patients (approximately 60-70%) are diagnosed with advanced-stage disease that is not suitable for radical resection with curative intent (2). For patients with unresectable iCCA, the current standard of systemic treatment is gemcitabine combined with platinum-based compounds, but the median survival is less than 12 months (3). Systemic and local therapy prior to surgery may increase the proportion of patients who are eligible for radical resection and reduce the postoperative recurrence rate. The traditional conversion therapies for advanced iCCA include systemic chemotherapy, transarterial chemoembolization (TACE), transarterial selective internal radiation/embolization therapy, and hepatic artery infusion (4). However, the optimal conversion treatment strategy and related survival benefits remain unclear.

In recent years, immunotherapy has yielded encouraging results in a variety of cancers, and National Comprehensive Cancer Network (NCCN) guidelines recommend pembrolizumab as a treatment choice for advanced cholangiocarcinoma with deficient mismatch repair (dMMR) and high microsatellite instability (MSI-H) (5). The relationship between PD-L1 expression in tumors and the efficacy of PD-1 inhibitors are still being investigated (6–8). PD-L1 is expressed in tumors from patients with iCCA, suggesting the feasibility of targeting the PD-1/PD-L1 pathway (9). For example, a study has preliminarily demonstrated that the expression of PD-L1 in tumor tissues of iCCA patients can be used as a biomarker to predict the efficacy of PD-1 inhibitor therapy (10). Furthermore, preliminary studies of immunotherapy combined with targeted therapy for iCCA are ongoing and have shown promising therapeutic prospects (11). Nevertheless, surgery for advanced iCCA following a combination of immunotherapy with targeted therapy has not been reported to date.

In the present report, we performed the first case study investigating a patient suffering from advanced intrahepatic cholangiocarcinoma with a high TMB and high expression of PD-L1 feature. Guided by the concept of precision medicine, the patient underwent an operation after successful conversion therapy with PD-1 blockade and lenvatinib. Encouragingly, this patient achieved pathological complete response (pCR) and long-term survival. Figure 1A shows the diagnosis, treatment and follow-up timeline for this patient.

CASE PRESENTATION

A 38-year-old female was admitted to the hospital on July 6, 2019, due to recurrent right upper abdominal pain. She had a history of chronic hepatitis B infection for 7 years that had not been treated. The patient’s performance status score was 1. Alpha-fetoprotein (AFP), abnormal prothrombin, carcinoembryonic antigen (CEA) and cancer antigen 19-9 (CA19-9) levels were within the normal range. Upper abdominal magnetic resonance imaging (MRI) revealed a mass in the right hepatic lobe with involvement of the inferior vena cava, along with retroperitoneal and right cardio-phrenic angle lymphatic metastases. Positron emission tomography-computed tomography (PET-CT) scans showed a huge mass with uneven increased metabolism in the right lobe of the liver, increased metabolism of the inferior vena cava nodule, increased metabolism of the right diaphragmatic nodule, and hypermetabolic lymph nodes near the abdominal aorta and anterior costal diaphragm (Figures 1B–F). The patient underwent a tumor needle biopsy guided by ultrasound on July 12, 2019. The pathohistological analysis of the tumor revealed poorly differentiated adenocarcinoma with necrotic components (Figure 2A). Upon immunohistochemical (IHC) analysis, the tumor was found to be positive for cytokeratin 18 and cytokeratin 19 (Figure 2B) while being negative for AFP and hepatocyte (Figures 2C, D), predisposed to cholangiocarcinoma. All indications suggested a diagnosis of stage IV iCCA (T2N1M0) according to the American Joint Committee on Cancer (AJCC) Cancer Staging Handbook, 8th edition (12). With the patient’s consent, whole-exome sequencing (WES) and deep sequencing of a panel of 733 genes was performed with the tissue obtained by the needle biopsy. The tissue was also analyzed for the expression of PD-L1 and the abundance of tumor-infiltrating lymphocytes (TILs). The tumor mutational burden was determined to be 21.77 mutations/Mb and defined as TMB-high (13). A total of 74 neoantigens were detected. No SNVs were detected in PMS2, MSH2, MSH6, or MLH1, suggesting pMMR, and the MSI status was stable. Prominent lymphocytes infiltration were observed in both tumor and stromal region, primarily CD8+ T cell, natural killer (NK) cells, and macrophages (Figures 2F–I). The density of these infiltrated lymphocytes at the tumor core were 1594 cells/mm², 986 cells/mm², and 3980 cells/mm² respectively. The tumor proportion score (TPS) of the PD-L1 expression level was 70% according to Allred criteria using the 22C3 monoclonal mouse anti-human PD-L1 antibody (Figure 2E). Based on these results, combined immunotherapy with multi-kinase inhibitor therapy was administered. After treatment with sintilimab (200 mg q3W) and lenvatinib (8 mg qd) for 7 cycles (21 weeks), MRI showed that the lesions in the right hepatic lobe and inferior vena cava had significantly decreased in size (Figure 3). The patient’s clinical efficacy can be assessed as stable disease (SD) according to the Response Evaluation Criteria in Solid Tumors (version 1.1) (14). The patient experienced only grade 1 adverse events of nausea and vomiting according to the standard CTCAE5.0 criteria.

The patient underwent right hemihepatectomy, retroperitoneal lymphadenectomy, right cardio-phrenic angle lymphadenectomy, and inferior vena cava embolectomy on December 10, 2019 (Figures 4A–C). The patient recovered well after surgery and no serious postoperative complications occurred. The total size of the lesion area in the postoperative specimen was 8.5×6×6cm. No tumor was found in the liver margin, the liver lesion area, groups 8a, 13, 16a, and 16b, the right cardio-phrenic angle lymphatic
tissue, or the tumorigenic thrombus of inferior vena cava after surgery. Extensive infiltration of T cells were observed in tumor margin and stromal. The patient underwent periodical MRI reexamination after surgery, which showed no recurrence in the coelom until March 3, 2021 (Figures 4D–F).

DISCUSSION

This case showed that negative surgical margins (R0 resection) can be achieved in a patient with advanced iCCA who received conversion therapy. Furthermore, the result suggests that the combination of lenvatinib with PD-1 inhibitors is an effective and safe conversion therapy strategy.

For primary liver cancer, the downstaging or conversion therapy approaches have been reported over 20 years ago (15, 16), but due to the lack of powerful systemic drugs at that time, the previous conversion therapy strategies mainly focused on local treatment or chemotherapy (17–20). Besides, there is a lack of research on conversion therapy for advanced iCCA currently (21).

Several clinical trials on immunotherapy of advanced biliary tract cancers are ongoing, some preliminary results were favorable (11, 22–24). A clinical trial of the combination of lenvatinib with immune checkpoint inhibitors resulted in an overall response rate (ORR) of 21.4% and disease control rate (DCR) of 92.9% in 14 patients with advanced iCCA who had received more than 2 prior anticancer therapy regimens (10). Several cases had also revealed supporting evidence on the promising effect of combined immunotherapy for advanced iCCA patients. For example, advanced iCCA patients with high TMB, high rate of insertion-deletion mutations (INDELS), and/or positive PD-L1 expression benefited from immunotherapy combined with chemotherapy (25, 26). These preliminary clinical trial results indicated that advanced iCCA patients with high TMB and positive PD-L1 expression were strongly associated with better immunotherapy or its combination with targeted or chemotherapy response (11).

Under the guidance of next-generation sequencing and tumor immune microenvironment testing, our case report suggests that immunotherapy combined with targeted therapy have more than a lethal effect on intrahepatic lesions but also can act on metastatic lesions in distant lymph node and tumorigenic thrombus, which may provide a superior conversion therapy option for unresectable iCCA patients and largely improve their benefit. But to clarify the accurate efficacy and the survival time...
FIGURE 2 | Hematoxylin-eosin (HE) staining and immunohistochemical analysis of liver tumor tissue from the needle biopsy. Pathological images show (A) HE staining (200×), (B) positive CK19 staining, (C) negative AFP staining, and (D) negative hepatocyte staining. (E) Immunohistochemical staining for PD-L1 expression (200×). Multiple fluorescence immunohistochemical images show (F) the CD8+ T cells, (G) the natural killer (NK) cells, (H) the macrophages, and (I) the merged images of the previous three images.

FIGURE 3 | MRI evaluation during preoperative systemic treatment. (A–C) indicate the maximum diameter of the lesion located in the liver, the maximum diameter of the lesion in (A–C) were 10.16cm, 8.93cm, and 8.77cm. (D–F) indicate the lesion located in the tumorigenic thrombus of the inferior vena cava, the maximum diameter of the lesion in (D–F) were 3.92cm, 3.28cm, and 3.00cm. Arrows in the figures indicate the position of lesions.
beneﬁt of this combination strategy, a prospective, multicenter, randomized controlled clinical study is necessary.

CONCLUSIONS

Our case provides a new insight that PD-1 blockade combined with TKIs can successfully convert advanced PD-L1-positive iCCA with a high TMB into resectable iCCA, and no tumor cells were found in the postoperative histopathological examination. The patient’s survival time had reached 25 months, as of August 2021.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article’s Supplementary Material. Further inquiries can be directed to the corresponding author.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the ethic committee of the Chinese PLA General Hospital (Approval No. S2018-111-01). The patients/participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identiﬁable images or data included in this article.

AUTHOR CONTRIBUTIONS

ZZ and WZ were responsible for WES, the whole-exome data analysis, the collection and analysis of clinical data. ZW supervised the pathology interpretation of the patient tissue samples. SL, HW, and BH participated in the operation, took care of patients, and communicated with patients. ZZ was responsible for writing the manuscript. SL was responsible for the analysis of data, data interpretation, and revision. All authors contributed to the article and approved the submitted version.

FUNDING

This study was funded by the National Key R&D Program of China (2017YFA0103003 and 2017YFA0103000), and the National Natural Science Foundation of China (81670950).

ACKNOWLEDGMENTS

The authors thank the patient and her family for allowing us to publish the report. We also thank Dr. Shuang Tong from 3D Medicines Inc. in Shanghai, China, for her valuable comments on the revision of the article.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2021.744571/full#supplementary-material
REFERENCES

1. Bertuccio P, Malvezzi M, Carioli G, Hashim D, Boffetta P, El-Serag HB, et al. Global Trends in Mortality From Intrahepatic and Extrahepatic Cholangiocarcinoma. *J Hepatol* (2019) 71(1):104–14. doi: 10.1016/j.jhep.2019.03.013

2. Bridgewater J, Galle PR, Khan SA, Llovet JM, Park JW, Patel T, et al. Guidelines for the Diagnosis and Management of Intrahepatic Cholangiocarcinoma. *J Hepatol* (2014) 60(6):1268–89. doi: 10.1016/j.jhep.2014.01.021

3. Valle J, Wasan H, Palmer DH, Cunningham D, Anthonys A, Maraveyas A, et al. Cisplatin Plus Gemcitabine Versus Gemcitabine for Biliary Tract Cancer. *New Engl J Med* (2010) 362(14):1273–81. doi: 10.1056/NEJMoa0908721

4. Akath C, Ejaz AM, Pawlik TM, Cloyd JM. Neoadjuvant Treatment Strategies for Intrahepatic Cholangiocarcinoma. *World J Hepatol* (2020) 12(10):693–708. doi: 10.4254/wjh.v12.i10.693

5. Overman MJ, Lai EC. Surgical Resection After Downsizing Chemotherapy for Initially Unresectable Huge Intrahepatic Cholangiocarcinoma to Surgical Treatment. *Ann Surg Oncol* (2017) 24(4):1006. doi: 10.1245/s10434-016-4727-0

6. Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, et al. Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment With Response to Anti-PD-1 Therapy. *Clin Cancer Res* (2014) 20(19):5064–74. doi: 10.1158/1078-0432.CCR-13-3271

7. Meng X, Huang Z, Teng F, Xing L, Yu J. Predictive Biomarkers in PD-1/PD-L1 Checkpoint Blockade Immunotherapy. *Cancer Treat Rev* (2015) 41(10):868–76. doi: 10.1016/j.ctrv.2015.11.001

8. Patel SP, Kurzrock R. PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy. *Mol Cancer Ther* (2015) 14(4):847–56. doi: 10.1158/1535-7163.MCT-14-0993

9. Valle JW, Kelley RK, Nervi B, Oh DY, Zhu AX. Biliary Tract Cancer. *Lancet* (2021) 397(10272):428–44. doi: 10.1016/S0140-6736(20)30153-7

10. Fontugne J, Augustin J, Pujals A, Compagnon P, Rousseau B, Luciani A, et al. PD-L1 Expression in Perihilar and Intrahepatic Cholangiocarcinoma. *Oncotarget* (2017) 8(15):24644–51. doi: 10.18632/oncotarget.15602

11. Lin J, Shi W, Zhao S, Hu J, Hou Z, Yao M, et al. Lenvatinib Plus Checkpoint Inhibitors in Patients (Pts) With Advanced Intrahepatic Cholangiocarcinoma (ICC): Preliminary Data and Correlation With Next-Generation Sequencing. *J Clin Oncol* (2018) 36(34_suppl):500–0. doi: 10.1200/JCO.2018.36.34_suppl.500

12. Cancer ACo. *AICC Cancer Staging Manual, 8th Edn*. New York: Springer (2017).

13. Zhuang W, Ma J, Chen X, Wang G, Lu J, Chen Y, et al. The Tumor Mutational Burden of Chinese Advanced Cancer Patients Estimated by a 381-Cancer-Genes Panel. *World J Hepatol* (2019) 11(5):354. doi: 10.4254/wjh.v11.i5.354

14. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New Response Evaluation Criteria in Solid Tumours: Revised RECIST Guideline (Version 1.1). *Eur J Cancer* (2009) 45(2):228–47. doi: 10.1016/j.ejca.2008.10.026

15. Lau WY, Ho SK, Yu SC, Lai EC, Liew CT, Leung TW. Salvage Surgery Following Downstaging of Unresectable Hepatocellular Carcinoma. *Ann Surg* (2004) 240(2):299–305. doi: 10.1097/01.sla.0000133123.11932.19

16. Tang ZY, Uy YQ, Zhou XD, Ma ZC, Lu JZ, Lin Zy, et al. Cyroablation and Sequential Resection for Surgically Verified Unresectable Hepatocellular Carcinoma: Evaluation With Analysis of 72 Patients. *World J Surg* (1995) 19(6):784–9. doi: 10.1007/BF02997771

17. Lau WY, Lai EC. Salvage Surgery Following Downstaging of Unresectable Hepatocellular Carcinoma-A Strategy to Increase Resectability. *Ann Surg Oncol* (2007) 14(12):3301–9. doi: 10.1245/s10434-007-9549-7

18. Rayar M, Sulpice L, Edeline J, Garin E, Levi Sandri GB, Meunier B, et al. Intra-Arterial Yttrium-90 Radioembolization Combined With Systemic Chemotherapy Is a Promising Method for Downstaging Unresectable Huge Intrahepatic Cholangiocarcinoma to Surgical Treatment. *Ann Surg Oncol* (2015) 22(9):3102–8. doi: 10.1245/s10434-014-4365-3

19. Ghiunitschi F, Lorgis V, Vincent J, Ladoire S, Guiu B. Hepatic Arterial Infusion of Gemcitabine Plus Oxaliplatin as Second-Line Treatment for Locally Advanced Intrahepatic Cholangiocarcinoma: Preliminary Experience. *Chemotherapy* (2013) 59(5):354–60. doi: 10.1159/000362223

20. Kato A, Shimizu H, Ohitsuka M, Yoshidome H, Yoshitomi H, Furukawa K, et al. Surgical Resection After Downsizing Chemotherapy for Initially Unresectable Locally Advanced Biliary Tract Cancer: A Retrospective Single-Center Study. *Ann Surg Oncol* (2013) 20(1):318–24. doi: 10.1245/s10434-012-2312-8

21. Fruscione M, Pickens BC, Baker EH, Martinie JF, Iannitti DA, Hwang JJ, et al. Conversion Therapy for Intrahepatic Cholangiocarcinoma and Tumor Downsizing to Increase Resection Rates: A Systematic Review. *Curr Probl Cancer* (2021) 45(1):100614. doi: 10.1016/j.ccrprt.2020.100614

22. Ueno M, Chung HC, Nagrial A, Marabelle A, Kelley RK, Xu L, et al. Pembrolizumab for Advanced Biliary Adenocarcinoma: Results From the Multicohort, Phase II KEYNOTE-158 Study. *Ann Oncol* (2018) 29:vii210. doi: 10.1093/annonc/mdy282.009

23. Ueno M, Ikeda M, Morizane C, Kobayashi S, Ohno I, Kondo S, et al. Nivolumab Alone or in Combination With Cisplatin Plus Gemcitabine in Japanese Patients With Unresectable or Recurrent Biliary Tract Cancer: A non-Randomised, Multicentre, Open-Label, Phase 1 Study. *Lancet Gastroenerol Hepatol* (2019) 7(4):611–21. doi: 10.1016/S2468-1253(19)30086-X

24. Arkenau HT, Martin-Liberal J, Calvo E, Penel N, Krebs MG, Herbst RS, et al. Ramucirumab Plus Pembrolizumab in Patients With Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open-Label, Phase 1 Trial (JVD). *Oncolologist* (2018) 23(12):1407–e1136. doi: 10.1634/theoncologist.2018-0844

25. Mou H, Yu L, Liao Q, Hou X, Wu Y, Cui Q, et al. Successful Response to the Combination of Immunotherapy and Chemotherapy in Cholangiocarcinoma With High Tumour Mutational Burden and PD-L1 Expression: A Case Report. *BMC Cancer* (2018) 18(1):1105. doi: 10.1186/s12885-018-2502-1

26. Sui M, Li Y, Wang H, Luo Y, Wen T, Wang X, et al. Two Cases of Intrahepatic Cholangiocellular Carcinoma With High Insertion-Deletion Ratios That Achieved a Complete Response Following Chemotherapy Combined With PD-1 Blockade. *J Immunother Cancer* (2019) 7(1):125. doi: 10.1186/s40425-019-0596-y

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Zhang, Zhang, Wang, Hu, Wang and Lu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided that the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.